Arístides Lopez Marquez
Investigador post-doc
Research group
Arístides López-Márquez graduated in Biochemistry in 2011 from the Autonomous University of Madrid and obtained his Ph.D. in Molecular Biology from the same university in 2017. He also holds a master's degree in Molecular Biomedicine.
Between 2018 and 2020 he carried out a first postdoctoral stage at the "Severo Ochoa" Molecular Biology Center in Madrid studying new advanced therapies and the generation of models through gene editing by CRISPR / Cas for rare genetically based diseases.
Since 2020 he is a senior postdoctoral researcher expert in new therapies based on gene editing and regulation at the Laboratory for Applied Research in Neuromuscular Diseases of the Institut Sant Joan de Déu.
Professional network profiles
Last Publications
- Martinez-Pizarro, Ainhoa, Pico, Sara, López-Marquez A, Rodriguez-Lopez, Claudia, Montalvo, Elena, Alvarez, Mar, Castro, Margarita, Ramon-Maiques, Santiago, Perez, Belen, Lucas, Jose J., Richard, Eva and Desviat, Lourdes R. PAH deficient pathology in humanized c.1066-11G>A phenylketonuria mice HUMAN MOLECULAR GENETICS . : .
- Castroflorio E, Pérez Berná AJ, López-Marquez A, Badosa-Gallego MC, Loza-Alvarez P, Roldan-Molina M and Jimenez-Mallebrera C The Capillary Morphogenesis Gene 2 Triggers the Intracellular Hallmarks of Collagen VI-Related Muscular Dystrophy INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 23(14): 1-15.
- Almici E, Chiappini V, López-Marquez A, Badosa-Gallego MC, Blázquez B, Caballero D, Montero J, Natera-de Benito D, Nascimento-Osorio A, Roldan-Molina M, Lagunas A, Jimenez-Mallebrera C and Samitier J Personalized in vitro Extracellular Matrix Models of Collagen VI-Related Muscular Dystrophies Frontiers in Bioengineering and Biotechnology . 10: 851825-851825.
Projects
- Project name:
- A nanomedicine platform for delivery of antisense oligonucleotides to treat neuromuscular diseases
- Leader
- Cecilia Jiménez Mallebrera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2023 LLAV 00079
- Starting - finishing date:
- 2024 - 2024
- Project name:
- Role of CMG2 and its associated effectors as potential therapeutic targets and in the pathophysiology of congenital muscular dystrophies due to collagen VI deficiency
- Leader
- Cecilia Jiménez Mallebrera
- Funding entities:
- Alexion Pharmaceuticals Inc.
- Code
- PCP00387
- Starting - finishing date:
- 2023 - 2026
- Project name:
- Cerrando la brecha terapeutica para Distrofias Musculares Congenitas. Estrategias para mejorar la eficacia, liberacion y seguridad de terapias basadas en CRISPR/Cas9 y oligonucleotidos
- Leader
- Cecilia Jiménez Mallebrera
- Funding entities:
- Instituto de Salud Carlos III (ISCIII), Fundació Privada per a la Recerca i la Docència Sant Joan de Déu - FSJD, Jiménez Mallebrera, Cecilia
- Code
- PI22/01382
- Starting - finishing date:
- 2023 - 2025